Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tobramycin kinetics during continuous ambulatory peritoneal dialysis.

C M Bunke, G R Aronoff, M E Brier

    Clinical Pharmacology and Therapeutics
    |July 1, 1983
    PubMed
    Summary

    This study determined tobramycin dosing for continuous ambulatory peritoneal dialysis (CAPD) patients. Intraperitoneal tobramycin dosing models were developed to guide therapy for infections in CAPD patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats.

    Hypertension (Dallas, Tex. : 1979)·2000
    Same author

    Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes.

    Hypertension (Dallas, Tex. : 1979)·2000
    Same author

    A cholesterol-lowering gene maps to chromosome 13q.

    American journal of human genetics·2000
    Same author

    Inhibition of pressure natriuresis in mice lacking the AT2 receptor.

    Kidney international·2000
    Same author

    [Water-electrolyte balance in clinical routine practice].

    Der Urologe. Ausg. A·1999
    Same author

    Peroxisome proliferator-activated receptor gamma gene locus is related to body mass index and lipid values in healthy nonobese subjects.

    Arteriosclerosis, thrombosis, and vascular biology·1999

    Area of Science:

    • Pharmacokinetics
    • Nephrology
    • Infectious Diseases

    Background:

    • Continuous ambulatory peritoneal dialysis (CAPD) requires careful drug dosing due to altered pharmacokinetics.
    • Establishing therapeutic guidelines for antibiotics like tobramycin in CAPD patients is crucial for effective treatment.

    Purpose of the Study:

    • To investigate tobramycin single-dose pharmacokinetics in CAPD patients.
    • To develop dosing guidelines for tobramycin in CAPD patients with gram-negative bacterial infections or peritonitis.

    Main Methods:

    • Studied tobramycin kinetics after intravenous (TOB-IV) and intraperitoneal (TOB-IP) administration (1.5 mg/kg dose).
    • Utilized the kinetic principle of superposition to predict plasma concentrations after repeated TOB-IP.
    • Developed dosing models for once-daily and per-exchange tobramycin administration.

    Related Experiment Videos

    Main Results:

    • TOB-IV yielded plasma concentrations above 3 mg/l at 12 hr (t 1/2 = 39.5 hr).
    • TOB-IP showed 52% absorption, peak plasma concentrations of 1.8 mg/l, and t 1/2 of 35 hr.
    • CAPD contributed 15-20% to total body clearance; models predicted effective steady-state concentrations with specific dosing regimens.

    Conclusions:

    • Tobramycin pharmacokinetics in CAPD patients differ based on administration route.
    • Proposed dosing models for tobramycin in CAPD patients can achieve therapeutic plasma concentrations.
    • These findings provide a basis for managing gram-negative bacterial infections in CAPD patients.